Diagnosis and treatment of cutaneous melanoma;Prise en charge du melanome cutane

Cancer/Radiotherapie

Volumn 2, Issue 6, 1998, Pages 732-746

  Thomas, L ^a   Cochran, A J ^b  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant therapy; Consensus conference; Cutaneous surgery; Cytostatic therapy; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DACARBAZINE; FOTEMUSTINE; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER SURGERY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HUMAN; IMMUNOTHERAPY; MELANOMA; PRIORITY JOURNAL; REVIEW; SEBORRHEIC KERATOSIS; SKIN CANCER; ADJUVANT THERAPY; CANCER STAGING; LYMPH NODE METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SKIN TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0032254505     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1278-3218(99)80016-X     Document Type: Article

References (258)

1. 1 Thomas L, Tranchand P, Bérard F, Secchi T, Colin C, Moulin G. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 1998 ; 197 : 11-7
2. 2 Brandberg Y, Bolund C, Michelson H, Mansson-Brahme E, Ringborg U, Sjoden PO. Perceived susceptibility to and knowledge of malignant melanoma: screening participants vs the general population. Prev Med 1996 ; 2 : 170-7
3. 3 Bartoli C, Bono A, Clemente C, Del Prato I, Zurrida S, Cascinelli N. Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 1996 ; 77 : 888-92
4. 4 Burton R. Aspects of screening for skin cancer. Cancer Forum 1996 ; 20 : 243-6
5. 5 De Rooij MJM, Rampen FHJ, Scheuten LJ, Neumann HAM. Volunteer melanoma screenings: follow-up, compliance, and outcome. Dermatol Surg 1997 ; 23 : 197-201
6. 6 Goldschmidt MH. Pigmented lesions of the skin. Clin Dermatol 1994 ; 12 : 507-14
7. 7 Gottlober P, Krahn G, Korting HC, Peter RU. Determination of diagnosis by dermatoscopy and 20 MHz-sonography: malignant melanoma versus basal cell carcinoma. Zur Hautkr 1996 ; 71 : 897-9
8. 8 Grimme H, Bergen E, Vanscheidt W, Schopf E, Simon JC. New aspects in diagnosis, therapy and follow-up of malignant melanoma. Med Welt 1996 ; 47 : 454-8
9. 9 Grover R, McKelvie M, Ross DA, Morgan BDG. Improving the early detection of malignant melanoma. Ann R Coll Surg Engl 1996 ; 78 : 176-9
10. 10 Hearing VJ, Gersten DM, Shrayer D, Law LW. Novel experimental approaches to melanoma diagnosis and therapy. J Dermatol 1994 ; 21 : 860-9
11. 11 Helsing P, Faye R, Langmark F. Cutaneous malignant melanoma. Correlation between tumor characteristics and diagnostic delay in Norwegian patients. Eur J Dermatol 1997 ; 7 : 359-61
12. 12 Herd RM, Cooper EJ, Hunter JAA, Claren KM, Chetty U, Watson ACH et al. Cutaneous malignant melanoma. Publicity, screening clinics and survival the Edinburgh experience 1982-90. Br J Dermatol 1995 ; 132 : 563-70
13. 13 Hoffman S, Yohn J, Robinson W, Norris D. Melanoma. I. Clinical characteristics. Hosp Pract 1994 ; 29 : 37-40
14. 14 Jakowatz JG, Meyskens FL. Evaluation and treatment of the patient with early melanoma. Compr Ther 1995 ; 21 : 46-50
15. 15 Kaudewitz P. Diagnostic and treatment of malignant melanoma from a dermatological point of view. Aktuel Chir 1996 ; 31 : 277-81
16. 16 MacKie RM. Melanoma prevention and early detection. Br Med Bull 1995 ; 51 : 570-83
17. 17 Marks R, Motley RJ. Skin cancer. Recognition and treatment. Drugs 1995 ; 50 : 48-61
18. 18 Simon JC, Grimme H, Bergen E, Vanscheidt W, Schopf E. Malignant melanoma of the skin. Fortschr Med 1995 ; 113 : 27-8
19. 19 Swetter SM. Malignant melanoma from the dermatologic perspective. Surg Clin North Am 1996 ; 76 : 1287-98
20. 20 Tilgen W. Early detection of malignant cutaneous cancers. Onkologie 1995 ; 3 : 64-71
21. 21 Yohn J, Hoffman S, Norris D, Robinson W. Melanoma. 2. Diagnosis and treatment. Hosp Pract 1994 ; 29 : 27-34
22. 22 Garbe C. Perspectives in dermatologic oncology. Zur Hautkr 1996 ; 71 : 416-24
23. 23 Adler MJ, White CR. Amelanotic malignant melanoma. Sem Cutaneous Med Surg 1997 ; 16 : 122-30
24. 24 Holder JE, Colloby RS, Fletcher A, Camp RDR. Amelanotic superficial spreading malignant melanoma mimicking Bowen's disease. Br J Dermatol 1996 ; 134 : 519-21
25. 25 Vandeput JJ, Kerre S. Amelanotic melanoma in situ. Eur J Plast Surg 1995 ; 18 : 252-4
26. 26 Cochran AJ, Bailly C, Cook M, Crotty K, Mihm M, Mooi W et al. Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Hum Pathol 1997 ; 28 : 1123-5
27. 27 Cochran AJ, Bailly C, Cook M, Crotty K, Mihm M, Mooi W et al. Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Virchows Arch 1997 ; 431 : 79-81
28. 28 Collina G, Deen S, Cliff S, Jackson P, Cook MG. Atypical dermal nodules in benign melanocytic naevi. Histopathology 1997 ; 31 : 97-101
29. 29 Del Mar CB, Green AC, Battistutta D. Patterns of excision and referral from primary care of melanocytic lesions. Melanoma Res 1997 ; 7 : 496-9
30. 30 Mehregan DA, Bergeon MT, Mehregan DR. Epidermotropic metastatic malignant melanoma. Cutis 1995 ; 55 : 225-7
31. 31 Meis Kindblom JM, Stenman G, Kindblom LG. Differential diagnosis of small round cell tumors. Semin Diagn Pathol 1996 ; 13 : 213-41
32. 32 Metcalf JS. Melanoma: criteria for histological diagnosis and its reporting. Semin Oncol 1996 ; 23 : 688-92
33. 33 Weinzweig N, Tuthill RJ, Yetman RJ. Desmoplastic malignant melanoma: a clinicohistopathologic review. Plast Reconstr Surg 1995 ; 95 : 548-55
34. 34 Rogers IR, Gibson LE. Mucosal, genital, and unusual clinical variants of melanoma. Mayo Clin Proc 1997 ; 72 : 362-6
35. 35 Hayes IM, Thompson JF, Quinn MJ. Malignant melanoma of the toenail apparatus. J Am Coll Surg 1995 ; 180 : 583-8
36. 36 Ishihara K. Malignant melanoma: its diagnosis and treatment -Discussion and case studies (VII) subungual melanoma no. 2. Biotherapy 1998 ; 12 : 335-9
37. 37 Kato T, Suetake T, Sugiyama Y, Tabata N, Tagami H. Epidemiology and prognosis of subungual melanoma in 34 Japanese patients. Br J Dermatol 1996 ; 134 : 383-7
38. 38 Umeda T, Yokoyama A, Hayashi O, Nishioka K. Treatments of longitudinal melanonychia. Jpn J Plast Reconstr Surg 1997 ; 40 : 265-70
39. 39 Folz BJ, Niemann AM, Lippert BM, Hauschild A, Werner JA. Mucosal melanoma of the upper aerodigestive tract. Laryngo Rhino Otol 1997 ; 76 : 289-94
40. 40 Egan CA, Bradley RR, Logsdon VK, Summers BK, Hunter GR, Vanderhooft SL. Vulvar melanoma in childhood. Arch Dermatol 1997 : 133 : 345-8
41. 41 Raber G, Mempel V, Jackisch C, Hundeiker M, Heinecke A, Kurzl R et al. Malignant melanoma of the vulva: report of 89 patients. Cancer 1996 ; 78 : 2353-8
42. 42 Doval DC, Rao CR, Sabitha KS, Vigayakumar M, Misra S, Mani K et al. Malignant melanoma of the oral cavity: report of 14 cases from a regional cancer centre. Eur J Surg Oncol 1996 ; 22 : 245-9
43. 43 Panizzon RG. Vulvar melanoma. Semin Dermatol 1996 ; 15 : 67-70
44. 44 Thomas L, Secchi T, Barrut D, Moulin G. The management of vulvar hyperpigmentation. Reprod Hum Horm 1996 ; 9 : 13-6
45. 45 Recommendations for the reporting of tissues removed as part of the surgical treatment of cutaneous melanoma. Mod Pathol 1997 ; 10 : 387-90
46. 46 Levene A, MacKie R. Pathological reporting of cutaneous malignant melanoma, Milano: WHO melanoma programme, 1992
47. 47 Brown M. Staging and prognosis of melanoma. Sem Cutaneous Med Surg 1997 ; 16 : 113-21
48. 48 Ishihara K. Diagnosis and treatment of malignant melanoma (VI) disease type, clinical symptoms and histopathological findings. Biotherapy 1996 ; 10 : 925-30
49. 49 Mussack T, Waldner H, Kharraz-Tavakol A. Risk factors for the development of lymph node metastasis in malignant melanoma. Zentralbl Chir 1996 ; 121 : 465-8
50. 50 Hofmann-Wellenhof R, Wonsche-Kahr I, Smolle J, Kerl H. Clinical and histological features of poor prognosis in cutaneous metastatic melanomas. J Cutaneous Pathol 1996 ; 23 : 199-204
51. 51 Lock Andersen J, Hou-Jensen K, Hansen JPH, Jensen NK, Sogaard H, Andersen PK. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1995 ; 29 : 141-8
52. 52 Fader DJ, Wise CG, Normolle DP, Johnson TM. The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care, J Am Acad Dermatol 1998 ; 38 : 742-51
53. 53 Garrison M, Nathanson L. Prognosis and staging in melanoma. Semin Oncol 1996 ; 23 : 725-33
54. 54 Kane WJ, Yugueros P, Clay RP, Woods JE. Treatment outcome for 424 primary cases of clinical stage I cutaneous malignant melanoma of the head and neck. Head Neck 1997 ; 19 : 457-65
55. 55 Provost N, Marghoob AA, Kopf AW, DeDavid M, Wasti Q, Bart RS. Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol 1997 ; 36 : 711-20
56. 56 Reintgen D, Albertini J, Miliotes G, Berman C, Cruse CW, Fenske N et al. The accurate staging and modern day treatment of malignant melanoma. Cancer Res Ther Control 1995 ; 4 : 183-97
57. 57 Romero JB, Stefanato CM, Kopf AW, Bart RS. Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol 1994 ; 20 : 175-8
58. 58 Hauschild A. The use of serological tumor markers for malignant melanoma. Onkologie 1997 ; 20 : 462-5
59. 59 Jung FA, Buzaid AC, Ross MI, Woods KV, Lee JJ, Albitar M et al. Evaluation of tyrosinase mRNA as a tumor marker in the blood of melanoma patients. J Clin Oncol 1997 ; 15 : 2826-31
60. 60 Stevens GL, Scheer WD, Levine EA. Detection of tyrosinase mRNA from the blood of melanoma patients. Cancer Epidemiol Biomark Prev 1996 ; 5 : 293-6
61. 61 Battayani Z, Grob JJ, Xerri L, Noe C, Zarour H, Houvaeneghel G et al. Polymerase chain reaction detection of circulating melanocytes as a prognostic marker in patients with melanoma. Arch Dermatol 1995 ; 131 : 443-7
62. 62 Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100 - A marker for disease monitoring in metastatic melanoma. Dermatology 1997 ; 194 : 208-12
63. 63 Buer J, Probst M, Franzke A, Duensing S, Haindl J, Volkenandt M et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer 1997 ; 75 : 1373-6
64. 64 Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Part A : General Topics. Eur J Cancer 1995 ; 31 : 924-8
65. 65 Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998 ; 16 : 1103-11
66. 66 Garbe C. Prolonged survival in disseminated melanoma and the impact of therapy. Analysis of the disease course in 22 patients surviving 2 years and more. Hautarzt 1996 ; 47 : 35-43
67. 67 The European Organization for Research and Treatment of Cancer (EORTC) malignant melanoma cooperative group 25th anniversary. Melanoma Res 1995 ; 5 : 69-72
68. 68 Koh HK. Cutaneous melanoma. N Engl J Med 1991 ; 325 : 171-82
69. 69 MacKie RM, Cascinelli N, Kirkwood JM, Ross MI, Santinami M, McCarthy WH. Clinical management of melanoma. Milano: WHO melanoma Programme, 1996
70. 70 Conférence de Consensus. Suivi des patients opérés d'un mélanome de stade I. Ann Dermatol Venereol 1995 ; 122 : 250-8
71. 71 Rümke P, Van Everdingen JJE. Consensus on the management of melanoma of the skin in the Netherlands. Eur J Cancer 1992 ; 28 : 756-60
72. 72 Ball AS, Thomas J. Surgical management of malignant melanoma. Br Med Bull 1995 ; 51 : 584-608
73. 73 Baron PL. The surgical management of melanoma: from diagnosis to local treatment. Semin Oncol 1996 ; 23 : 714-8
74. 74 Behan FC, Terrill PJ, Breidahl A, Cavallo A, Ashton M, Bennett T et al. Island flaps including the Bezier type in the treatment of malignant melanoma. Aust New Zealand J Surgery 1995 ; 65 : 870-80
75. 75 Bursa V, Pizinger K, Solc J, Stuchlova A, Sormova K. Our experience with operative treatment of malignant melanoma. Acta Chir Plast 1996 ; 38 : 21-3
76. 76 Cohen GL, Falkson CI. Current treatment options for malignant melanoma. Drugs 1998 ; 55 : 791-9
77. 77 Fraker DL. Surgical issues in the management of melanoma. Curr Opin Oncol 1997 ; 9 : 183-8
78. 78 Geraghty PJ, Johnson TM, Sondak VK, Chang AE. Surgical therapy of primary cutaneous melanoma. Semin Surg Oncol 1996 ; 12 ; 386-93
79. 79 Hudson DA, Krige JEJ. Results of 3 cm excision margin for melanoma of the scalp. J R Coll Surg Edinburgh 1995 ; 40 : 93-6
80. 80 Huth JF. Surgical treatment of malignant melanoma. Sem Cutaneous Med Surg 1997 ; 16 : 159-64
81. 81 Kaufmann R. Surgical treatment of cutaneous melanomas. Zur Hautkr 1997 ; 72 : 161-5
82. 82 Khorshid SM, Pinney E, Bishop JAN. Melanoma excision by general practitioners in North-East Thames region, England. Br J Dermatol 1998 ; 138 : 412-7
83. 83 Kokubu I, Sugihara T, Minakawa H. Surgical treatment of cutaneous malignant melanoma. Jpn J Plast Reconstr Surg 1997 ; 40 : 65-75
84. 84 Kroon BBR, Nieweg OE, Hoekstra HJ, Lejeune FJ. Principles and guidelines for surgeons: management of cutaneous malignant melanoma. Eur J Surg Oncol 1997 ; 23 : 550-8
85. 85 Modena S, Peroni A, Beghini D, Massocco A, De Agostini F, Zanza A et al. Limited surgery in the treatment of early lesions of cutaneous melanoma. Chirurgia 1994 ; 7 : 234-6
86. 86 Robinson JK. Margin control for lentigo maligna. J Am Acad Dermatol 1994 ; 31 : 79-85
87. 87 Salopek TG, Slade JM, Marghoob AA, Rigel DS, Kopf AW, Bart RS et al. Management of cutaneous malignant melanoma by dermatologists of the American Academy of Dermatology. II. Definitive surgery for malignant melanoma. J Am Acad Dermatol 1995 ; 33 : 451-61
88. 88 Snow SN, Mohs FE, Oriba HA, Dudley CM, Leverson G, Hetzer M. Cutaneous malignant melanoma treated by mohs surgery: review of the treatment results of 179 cases from the Mohs melanoma registry. Dermatol Surg 1991 ; 23 : 1055-60
89. 89 Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997 ; 37 : 236-45
90. 90 Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol 1997 ; 37 : 422-9
91. 91 Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I melanoma of the limbs. Mayo Clin Proc 1986 ; 61 : 697-705
92. 92 Hochwald SN, Coit DG. Role of elective lymph node dissection in melanoma. Semin Surg Oncology 1998 ; 14 : 276-82
93. 93 Koller J, Rettenbacher L, Gmeiner D, Dietze O. Selective regional lymphadenectomy: a new conception in the treatment of malignant melanoma. Zur Hautkr 1997 ; 72 : 492-6
94. 94 Piepkorn M, Weinstock MA, Barnhill RL. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Arch Dermatol 1997 ; 133 : 995-1002
95. 95 Ross MI. Surgery and other local-regional modalities for all stages of melanoma. Curr Opin Oncol 1994 ; 6 : 197-203
96. 96 Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997 ; 133 : 1014-20
97. 97 Cottingham T, Larson J, Delaney JP, Zachary C, Glass LF. Sentinel node dissection in the treatment of melanoma: report of three cases and review of the literature. Dermatol Surg 1997 ; 23 : 113-9
98. 98 Emilia JCD, Lawrence W, Jr, Sentinel lymph node biopsy in malignant melanoma: the standard of care? J Surg Oncol 1997 ; 65 : 153-4
99. 99 Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm, FK et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992 ; 127 : 392-9
100. 100 Karakousis CP, Najibi S, Trunk J. Sentinel node biopsy in malignant melanoma. J Surg Oncol 1997 ; 66 : 282-4
101. 101 Leong SPL, Steinmetz I, Habib FA, McMillan A, Gans JZ, Allen RE et al. Optimal selective sentinel lymph node dissection in primary malignant melanoma. Arch Surg 1997 ; 132 : 666-73
102. 102 Reintgen DS, Conrad AJ. Detection of occult melanoma cells in sentinel lymph nodes and blood. Semin Oncol 1997 ; 24 : S4-11
103. 103 Thompson JF, McCarthy WH, Bosch CMJ, O'Brien CJ, Quinn MJ, Paramaesvaran S et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes, Melanoma Res 1995 ; 5 : 255-60
104. 104 Bachter D, Balda BR, Vogt H, Buchels H. Sentinel lymphonodectomy using a gamma-probe. A new strategic in the treatment of malignant melanoma. Hautarzt 1996 ; 47 : 754-8
105. 105 Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1994 ; 75 : 726-34
106. 106 Ishihara K. Chemotherapy for malignant melanoma. Jpn J Cancer Chemother 1995 ; 22 : 23-7
107. 107 Pectasides D, Alevizakos N, Bafaloukos D, Tzonou A, Asimakopoulos G, Varthalitis I et al. Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological Stage II malignant melanoma. Am J Clin Oncol Cancer Clin Trials 1994 ; 17 : 55-9
108. 108 Alexander HR, Fraker DL, Bartlett DL. Isolated limb perfusion for malignant melanoma. Semin Surg Oncol 1996 : 12 : 416-28
109. 109 Bartlett DL, Ma G, Alexander HR, Libutti SK, Fraker DL. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics. Cancer 1997 ; 80 : 2084-90
110. 110 Bryant PJ, Balderson GA, Mead P, Egerton WS. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival. World J Surg 1995 ; 19 : 363-8
111. 111 Cavaliere R, Cavaliere F, Deraco M, Di Filippo F, Santinami M, Monica S et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIAB melanoma patients. Comparison of two experiences. Melanoma Res 1994 ; 1 : 5-11
112. 112 Decian F, Mondini G, Demarchi R, Muzio G, Sementa A, Bocchio MM et al. Conventional isolated hyperthermic antiblastic perfusion in the treatment of recurrent limb melanoma. Anticancer Res 1996 ; 16 : 2017-24
113. 113 Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol 1996 ; 14 : 479-89
114. 114 Lienard D, Eggermont AM, Kroon BBR, Koops HS, Lejeune FJ. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol 1998 ; 14 : 202-9
115. 115 Sonneveld EJA, Vrouenraets BC, Van Geel BN, Eggermont AMM, Klaase JM, Nieweg OE et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol 1996 ; 22 : 521-7
116. 116 Thompson JF, Kam PCA, Saw RPM, Shannon KF, Boyle SR, Waugh RC. Isolated limb infusion for melanoma: results of an elective double infusion protocol. Reg Cancer Treat 1995 ; 8 : 3-4
117. 117 Wurl P, Eichfeld U, Pauer HD, Glaser A, Rose U, Dralle H. Technique and results of regional hyperthermic cytostatic arm perfusion for malignant melanoma. Surg Today 1997 ; 27 : 719-25
118. 118 Engin K, Leeper DB, Tupchong L, Waterman FM. Thermoradiotherapy in the management of superficial malignant tumors. Clin Cancer Res 1995 ; 1 : 139-45
119. 119 Goldschmidt H, Breneman JC, Breneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 ; 30 : 157-86
120. 120 Halpern JN. Radiation therapy in skin cancer: a historical perspective and current applications. Dermatol Surg 1997 ; 23 : 1089-93
121. 121 Ishihara K. Malignant melanoma: its diagnosis and treatment-radiation therapy XII. Biotherapy 1997 ; 11 : 117-21
122. 122 Jenrette JN. Malignant melanoma: the role of radiation therapy revisited. Semin Oncol 1996 ; 23 : 759-62
123. 123 Lujan-Castilla PJ, Herrera Calderon W, Gainza Lagunes S, Garcia Gonzalez H, Diaz Rodriguez L. Radiotherapy in malignant melanoma. Experience with hypofraction in the treatment of local recurrence. Rev Inst Nac Cancerol 1997 ; 43 : 142-6
124. 124 Parker RG. Radiation therapy for skin neoplasms. Clin Dermatol 1995 ; 13 : 579-58
125. 125 Schmidt Ullrich RK, Johnson CR. Role of radiotherapy and hyperthermia in the management of malignant melanoma. Semin Surg Oncol 1996 ; 12 : 407-15
126. 126 Stratigos AJ, Sober AJ. An update on therapy of cutaneous melanoma. Skin Cancer 1996 ; 11 : 45-61
127. 127 Voss N, Kim Sing C. Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin 1998 ; 16 : 313-20
128. 128 Vtyurin BM, Medvedev VS, Anikin VA, Ivanova LF, Ivanov VN, Fomin SD et al. Neutron brachytherapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1994 ; 28 : 703-9
129. 129 Fujimoto T, O'Donnell MA, Szilvasi A, Yang H, Duda RB. Bacillus Calmette-Guerin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which Inhibits B16F10 melanoma cell growth in vitro. Cancer Immunol Immunother 1996 ; 42 : 280-4
130. 130 Henz BM, Macher E, Brocker EB, Suciu S, Steerenberg PA, Jung E et al. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781). Dermatology 1996 ; 193 : 105-9
131. 131 Hersey P. Melanoma vaccines: prospects for the treatment of melanoma. Expert Opin Invest Drugs 1997 ; 6 : 267-77
132. 132 Hoon DSB, Yuzuki D, Hayashida M, Morton DL. Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 1995 ; 154 : 730-7
133. 133 Sondak VK, Wolfe JA. Adjuvant therapy for melanoma. Curr Opin Oncol 1997 ; 9 : 189-204
134. 134 Weil M, Borel C, Rixe O, Antoine E, Auclerc G, Banzet P et al. Adjuvant treatment of excised melanoma in stage I. Ann Dermatol Venereol 1995 ; 122 : 315-8
135. 135 Grob J, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B et al. Randomized trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1,5 mm without clinically detectable node metastases. Lancet 1998 ; 351 : 1905-10
136. 136 Kleeberg UR, Eggermont AMM. Twenty-five years of pluridisciplinary approach for melanoma patients. The European Organization on Research and Treatment of Cancer Melanoma Cooperative Group (EORTC-MCG). Melanoma Res 1995 ; 5 : 69-72
137. 137 Stark JJ, Dillman RO, Schulof R, Wiemann MC, Barth NM, Honeycutt PJ et al. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: Final results of a phase I-II study of the cancer biotherapy research group and the mid-Atlantic Oncology Program. Cancer 1998 ; 82 : 1677-81
138. 138 Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P et al. Adjuvant interferon alfa-2a treatment in reseeted primary stage II cutaneous melanoma. J Clin Oncol 1998 ; 16 : 1425-9
139. 139 Saida T. Treatment of malignant melanoma: recent advances and perspectives. Jpn J Cancer Chemother 1997 ; 24 : 10-5
140. 140 Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997 ; 15 : 2351-8
141. 141 Rusciani L, Petraglia S, Alotto M, Calvieri S, Vezzoni G. Postsurgical adjuvant therapy for melanoma: evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up. Cancer 1997 ; 79 : 2354-60
142. 142 Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996 ; 14 : 7-17
143. 143 Kuhn CA, Hanke CW, Bystryn JC. Current status of melanoma vaccines. Dermatol Surg 1997 ; 23 : 649-55
144. 144 Hoon DSB, Irie RF. Current status of human melanoma vaccines. Can they control malignant melanoma? BioDrugs 1997 ; 7 : 66-84
145. 145 Mastrangelo MJ, Maguire HC, Sato T, Nathan FE, Berd D. Active specific immunization in the treatment of patients with melanoma. Semin Oncol 1996 ; 23 : 773-81
146. 146 Bystryn JC, Shapiro RL, Harris M, Roses DF, Oratz R. Use of vaccines in treatment of malignant melanoma. Clin Dermatol 1996 ; 14 : 337-41
147. 147 Morton DL, Barth A. Vaccine therapy for malignant melanoma. Cancer J Clin 1996 ; 46 : 225-44
148. 148 Mitchell M. Active specific immunotherapy of melanoma. Br Med Bull 1995 ; 51 : 631-46
149. 149 Merimsky O, Shoenfeld Y, Chaitchik S, Yecheskel G, Fishman P. Antigens and antibodies in malignant melanoma. Tumor Biol 1994 ; 15 : 188-202
150. 150 Moloney DM, Gordon DJ, Briggs JC, Rigby HS. Recurrence of thin melanoma: how effective is follow-up? Br J Plast Surg 1996 ; 49 : 409-13
151. 151 Orfanos CE, Jung EG, Rassner G, Wolff HH, Garbe C. Position paper of the Melanoma Committee of the German Dermatological Society on cutaneous malignant melanoma, with recommendations for diagnostic, treatment and follow-up. Status 1993/94. Hautarzt 1994 ; 45 : 285-91
152. 152 Sylaidis P, Gordon D, Rigby H, Kenealy J. Follow-up requirements for thick cutaneous melanoma. Br J Plast Surg 1997 ; 50 : 349-53
153. 153 Bosserhoff A-K, Kaufmann M, Kaluza B, Bartke I, Zinrngilb H, Hein R et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res 1997 ; 57 : 3149-53
154. 154 Brenner W, Klomp HJ, Bohuslavizki KH, Szonn B, Wolf H, Clausen M et al. (201)T1 whole-body scintigraphy in patients with malignant melanoma. Nucl Med Commun 1997 ; 18 : 230-4
155. 155 Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996 ; 6 : 325-9
156. 156 Muller C, Le Pape A, Musset M, Baulieu JL, Delarue A, Binz H et al. Scintigraphy with (99m)Technetium-J001X acylated polygalactoside in melanoma recurrence. Eur J Dermatol 1995 ; 5 : 600-6
157. 157 Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF et al. Localization of (111)indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy: augmentation with cyclophosphamide and correlation with response. Cancer 1994 ; 73 : 1731-7
158. 158 Rodot S, Darcourt J, Bussiere F, Lacour JP, Migneco O, Thyss A et al. A radiolabelled iodobenzamide for malignant melanoma staging. Melanoma Res 1994 ; 4 : 307-12
159. 159 Semple JL, Gupta AK, From L, Hara KA, Sauder DN, Foster FS et al. Does high-frequency (40-60 MHz) ultrasound imaging play a role in the clinical management of cutaneous melanoma? Ann Plast Surg 1995 ; 34 : 599-606
160. 160 Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996 ; 23 : 737-43
161. 161 Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995 ; 181 : 193-201
162. 162 Cockerell CJ, Lyons JH. Elective regional lymph node dissection in cutaneous melanoma. J Dermatol Treat 1995 ; 6 : 127-34
163. 163 Cole DJ, Baron PL. Surgical management of patients with intermediate thickness melanoma: current role of elective lymph node dissection. Semin Oncol 1996 ; 23 : 719-24
164. 164 Lyons JH, III, Cockerell CJ. Elective lymph node dissection for melanoma. J Am Acad Dermatol 1994 ; 30 : 467-80
165. 165 Omlor G, Dill Muller D, Gross G, Kautz G, Schuder G, Zaun H et al. Elective lymph node dissection (ELND) in malignant melanomas - The role of ultrasound. Zentralbl Chir 1996 ; 121 : 469-73
166. 166 Ramnath EM, Kamath D, Brobeil A, Stall A, Kamath V, Cruse CW et al. Lymphatic mapping for melanoma: Long-term results of regional nodal sampling with radioguided surgery. Cancer Control 1997 ; 4 : 483-90
167. 167 Ross MI. Surgical management of stage I and II melanoma patients: approach to the regional lymph node basin. Semin Surg Oncol 1996 ; 12 : 394-401
168. 168 Sim FH, Nelson TE, Pritchard DJ. Malignant melanoma: Mayo clinic experience. Mayo Clin Proc 1997 ; 72 : 565-9
169. 169 Sutherland CM, Chmiel JS, Bieligk S, Henson DE, Winchester DP. Patient characteristics, treatment, and outcome of unknown primary melanoma in the United States for the years 1981 and 1987. Am Surg 1996 ; 62 : 400-6
170. 170 Tsuchida Y, Fukuda O, Ikeda S, Suzuki T, Kiyohara Y. The surgical management of a parotid node metastasis of a malignant skin tumor. Jpn J Plast Reconstr Surg 1995 ; 38 : 1043-50
171. 171 Winter H, Kuchler I, Aurisch R. Improved prognosis in melanoma surgery by excision of tumour, lymph channels and elective lymph node dissection in continuity. Ten years experiences after introduction of the lymphatic outflow scintigraphy. Aktuel Chir 1996 ; 31 : 282-90
172. 172 Kirkwood JM, Resnick GD, Cole BF. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 1997 ; 24 : S4-16
173. 173 Bear HD, Hamad GG, Kostuchenko PJ. Biologic therapy of melanoma with cytokines and lymphocytes. Semin Surg Oncol 1996 ; 12 : 43645
174. 174 Berthier-Vergnes O, Portoukalian J, Leftheriotis E, Dore JF. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates. Cancer Res 1994 ; 54 : 2433-9
175. 175 Bonnekoh B, Bickenbach JR, Roop DR. Immunological gene therapy approaches for malignant melanoma. 2. Preclinical studies and clinical strategies. Skin Pharmacol 1997 ; 10 : 105-25
176. 176 Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994 ; 12 : 1036-44
177. 177 Plaksin D, Porgador A, Vadai E, Feldman M, Schirrmacher V, Eisenbach L. Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 1994 ; 59 : 796-801
178. 178 Eggermont AMM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv 1995 ; 26 : 335-50
179. 179 Gutman M, Abu-Abid S, Inbar M, Lev D, Chaitchik S, Sorkin P et al. Intra-arterial chemotherapy with concomitant hemofiltration (chemofiltration) for treatment of loco-regional or pelvic metastases from malignant melanoma. Melanoma Res 1996 ; 6 : 167-71
180. 180 Klaase JM, Kroon BBR, Beijnen JH, Van Slooten GW, Van Dongen JA. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994 ; 70 : 151-3
181. 181 Nakayama J, Takeuchi M, Mayumi H, Nagae S, Matsuda K, Yasui H et al. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion and concomitant infusion of either carboplatin or beta -interferon. J Dermatol 1996 ; 23 : 6-15
182. 182 Schlag PM, Kettelhack C. Isolated limb perfusion with tumor necrosis factor and melphalan - A new method in the treatment of regional melanoma metastases and locally advanced soft-tissue sarcoma. Onkologie 1995 ; 18 : 123-4
183. 183 Thompson JF, Waugh RC, Saw RPM, Kam PCA. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat 1994 ; 7 : 3-4
184. 184 Vaglini M, Santinami M, Manzi R, Inglese MG, Santoro N, Persiani L et al. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Melanoma Res 1994 ; 1 : 35-8
185. 185 Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer 1994 ; 73 : 483-92
186. 186 Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg 1996 ; 83 : 1319-28
187. 187 Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BBR. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998 ; 14 : 224231
188. 188 Kirkwood JM. Systemic therapy of melanoma. Curr Opin Oncol 1994 ; 6 : 204-11
189. 189 El Kassas H, Kirkwood JM. Adjuvant application of interferons. Semin Oncol 1996 ; 23 : 737-43
190. 190 Fletcher WS, Pommier RF, Lum S, Wilmarth TJ. Surgical treatment of metastatic melanoma. Am J Surg 1998 ; 175 : 413-7
191. 191 Ollila DW, Morton DL. Surgical resection as the treatment of choice for melanoma metastatic to the lung. Chest Surg Clin North Am 1998 ; 8 : 183-96
192. 192 Gieger M, Wu JK, Ling MN, Wazer D, Tsai JS, Engler MJ. Response of intracranial melanoma metastases to stereotactic radiosurgery. Radiat Oncol Invest 1997 ; 5 : 72-80
193. 193 Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry IV D et al. Melanoma of unknown primary site: presentation, treatment, and prognosis - A single institution study. Cancer 1997 ; 79 : 1816-21
194. 194 Heiss MM, Kaden AH, Allgayer H, Piltz S, Jauch KW, Schildberg FW. Prognostic influence of metastases resection in malignant melanoma. Aktuel Chir 1996 ; 31 : 294-7
195. 195 Luther H, Lubowietzki M, Rochling A, Kissler M, Altmeyer P. Long-term survival of metastatic melanoma after repeated surgical interventions. Eur J Dermatol 1996 ; 6 : 515-8
196. 196 Petit T, Janser JC, Petit JC. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 1996 ; 78 : 571
197. 197 Hahka-Kemppinen M, Muhonen T, Virolaínen M, Jekunen A, Asko-Seljavaara S, Pyrhonen S. Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy. Br J Dermatol 1995 ; 132 : 973-7
198. 198 Klein ES, Davidson B, Apter S, Azizi E, Ben Ari GY. Total abdominal perfusion (TAP) in the treatment of abdominal metastatic melanoma. J Surg Oncol 1994 ; 57 : 134-7
199. 199 Schadendorf D, Czarnetzki BM. Chemoresistance of malignant melanoma. Mechanisms and possible modulation. Hautarzt 1994 ; 45 : 678-84
200. 200 Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human malignant melanoma: a retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994 ; 73 : 103-8
201. 201 Nathan FE, Mastrangelo MJ. Systemic therapy in melanoma. Semin Surg Oncol 1998 ; 14 : 319-27
202. 202 Hansson J. Systemic therapy of malignant melanoma. Med Oncol 1997 ; 14 : 73-81
203. 203 Retsas S. Systemic treatment of malignant melanoma: grade is as important as stage. Clin Exp Dermatol 1997 ; 22 : 67-71
204. 204 Tamm I, Grimme H, Bergen E, Simon JC, Schopf E, Mertelsmann R et al. Dacarbazine and interferon alpha for stage IV malignant melanoma. Oncology Switzerland 1997 ; 54 : 270-4
205. 205 Atkins MB. The treatment of metastatic melanoma with chemotherapy and biologics. Curr Opin Oncol 1997 ; 9 : 205-13
206. 206 Lopez Alvarez MP, Valenzuela JC, Reina JJ, Bolanos M, Gomez MJ, Viana A et al. Prospective study with dacarbacin plus alpha interferon 2b as first line therapy in metastatic melanoma. Neoplasia 1997 ; 14 : 51-6
207. 207 Ishihara K. Malignant melanoma: its diagnosis and treatment XI, Chemotherapy for melanoma. Biotherapy 1996 ; 10 : 1465-71
208. 208 Mc Clay EF, Mc Clay ME. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 1996 ; 23 : 744-53
209. 209 Benhammouda A, Auclerc G, Coeffic D, Weil M, Nizri D, Soubrane C et al. Chemotherapy and immunotherapy for disseminated malignant melanomas. Presse Med 1996 ; 25 : 1690-7
210. 210 Rudolf Z, Strojan P. DTIC vs. IFN- alpha plus DTIC in the treatment of patients with metastatic malignant melanoma. Neoplasma 1996 ; 43 : 93-7
211. 211 Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996 ; 35 : 149-58
212. 212 Falkson CI. Treatment of metastatic malignant melanoma. Anti Cancer Drugs 1995 ; 6 : 709-16
213. 213 Anderson CM, Buzaid AC, Legha SS. Systemic treatments for advanced cutaneous melanoma. Oncology 1995 ; 9 : 1149-58
214. 214 Betticher DC, Lee SM, Morris C, Clemons M, Thatcher N. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: HIGH response rate and prolongation of response duration occur in different patient subpopulations. Melanoma Res 1995 ; 5 : 277-82
215. 215 Lee SM, Betticher DC, Thatcher N. Melanoma: chemotherapy. Br Med Bull 1995 ; 51 : 609-30
216. 216 Bajetta E, Di Leo A, Zampino MG, Sertoli MR, Comella G, Barduagni M et al. Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994 ; 12 : 806-11
217. 217 Brocker EB, Bohndorf W, Kampgen E, Trcka J, Messer P, Tilgen W et al. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study. Melanoma Res 1996 ; 6 : 399-401
218. 218 Comella P, Daponte A, Casaretti R, Ionna F, Fiore F, Presutti F et al. Fotemustine and dacarbazine plus recombinant interferon alpha2a in the treatment of advanced melanoma. Eur J Cancer Part A 1997 ; 33 : 1326-9
219. 219 Falkson CI, Falkson G, Falkson HC. Phase II trial of fotemustine in patients with metastatic malignant melanoma. Invest New Drugs 1994 ; 12 : 251-4
220. 220 Bajetta E, Rimassa L, Gamaghi C, Del Vechhio M, Cello L, Cassata A. Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma. Tumori 1998 ; 84 : 48-51
221. 221 Richard MA, Grob JJ, Zarrour H, Basseres N, Bizzari JP, Gerard B et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Res 1998 ; 8 : 170-4
222. 222 Johnston SRD, Constenla DO, Moore J, Atkinson H, A'Hem RP, Dadian G et al. Randomized phase II trial of BCDT (carmustine [BCNU], cisplatin, dacarbazine [DTIC] and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer 1998 ; 77 : 1280-6
223. 223 Rolski J, Zemelka T, Wiczynska B, Rysz B, Budzanowska E. The effect of chemotherapy with cisplatin, dacarbazine, lomustine and tamoxifen in patients with malignant melanoma. Przegl Dermatol 1997 ; 84 : 357-61
224. 224 Punt CJA, Van Herpen CML, Jansen RLH, Vreugdenhil G, Muller EW, De Mulder PHM. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study. Br J Cancer 1997 ; 76 : 266-9
225. 225 Chmielowska E, Potemski P, Zambrano-Quispe O, Czernek U, Pluzanska A. The combined chemotherapy with cisplatin, dacarbazine and tamoxifen in melanoma patients with recurrent disease - a preliminary report. Przegl Dermatol 1996 ; 83 : 489-92
226. 226 Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon. Ann Oncol 1996 ; 7 : 827-35
227. 227 Tessier MH, Mansat E, Legoux B, Litoux P, Dreno B. Combined treatment with dacarbazine, cisplatin and interferon alpha in metastatic melanoma. Ann Dermatol Venereol 1996 ; 123 : 538-42
228. 228 Tan EH, Ang PT. Combination chemotherapy (dacarbazine, carmustine, cisplatin, and tamoxifen) in advanced melanoma. Singapore Med J 1996 ; 37 : 165-7
229. 229 Flaherty LE, Liu PY, Mitchell MS, Fletcher WS, Walker MJ, Goodwin JW et al. The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group (SWOG-8921). Am J Clin Oncol Cancer Clin Trials 1996 ; 19 : 108-13
230. 230 Perrot JL, Lanthier K, Benoit F, Graille MC, Guy C, Bertheas MF et al. Myelodysplastic syndromes after fotemustine and dacarbazine therapy for malignant melanoma. Ann Dermatol Venereol 1995 ; 122 : 663-6
231. 231 Feun LG, Savaraj N, Moffat F, Robinson D, Liebmann A, Hurley J et al. Phase II trial of recombinant interferon-alpha with BCNU, cisplatin, DTIC and tamoxifen in advanced malignant melanoma. Melanoma Res 1995 ; 5 : 273-6
232. 232 Abbott KL, Harman GS. Combination chemotherapy for disseminated malignant melanoma. Anti Cancer Drugs 1995 ; 6 : 489-97
233. 233 Antoine EC, Rixe O, Vuillemin E, Benhammouda A, Borel C, Ghironzi GC et al. A phase II study of tamoxifen combined with cisplatin-interleukin 2 and alpha-interferon in metastatic melanoma. Am J Clin Oncol Cancer Clin Trials 1995 ; 18 : 421-4
234. 234 Rixe O, Borel C, Paraiso D, Benhammouda A, Petit T, Antoine E et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. Melanoma Res 1995 ; 5 : 419-24
235. 235 Mansat-Krzyzanowska E, Dreno B. Combined therapy with dacarbazine, vindesine and interferon-alpha in the treatment of metastatic melanoma. Ann Dermatol Venereol 1994 ; 121 : 884-7
236. 236 Chang J, Atkinson H, A'Hern R, Lorentzos A, Gore ME. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. Part A: Gen Top. Eur J Cancer 1994 : 30 : 2093-5
237. 237 Gasparini G, McClay EF, McClay ME. Tamoxifen and chemotherapy in the treatment of metastatic melanoma: Are there other possible mechanisms explaining their potentiation? [4]. J Clin Oncol 1994 ; 12 : 1994-6
238. 238 Buzaid AC, Legha SS, Balch CM, Ross M, Ring S, Plager C et al. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer 1994 ; 74 : 2476-82
239. 239 Philip PA, Carmichael J, Tonkin K, Ganesan TA, Harris AL. A phase II study of high-dose hydroxyurea and dacarbazine (DTIC) in the treatment of metastatic malignant melanoma. Part A Gen Top. Eur J Cancer 1994 ; 30 : 1027-9
240. 240 Perez Manga G, Gonzalez Del Val R. Is tamoxifen associated to chemotherapy useful in the treatment of disseminated melanoma? Neoplasia 1994 ; 11 : 71-2
241. 241 Perez Manga G, Gonzalez Del Val R, Martinez Del Prado P et al. Treatment of disseminated malignant melanoma. The role of hormonetherapy. Oncologia Spain 1994 ; 17 : 17-22
242. 242 McClay EF, McClay MET. Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? J Clin Oncol 1994 ; 12 : 617-26
243. 243 Rudenstam CM. Open trials in cutaneous malignant melanoma. Eur J Surg Oncol 1996 ; 22 : 128-30
244. 244 Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcony L et al. Radiation therapy for nodal disease in malignant melanoma. World J Surg 1995 ; 19 : 369-71
245. 245 Isokangas OP, Muhonen T, Kajanti M, Pyrhonen S. Radiation therapy of intracranial malignant melanoma. Radiother Oncol 1996 ; 38 : 139-44
246. 246 Antoine EC, Benhammouda A, Bernard A, Youssef A, Mortier N, Gozy M et al. Salpetriere hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am 1997 ; 1 : S16-S21
247. 247 Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N. Development and results of biochemotherapy in metastatic melanoma: the University of Texas MD Anderson Cancer Center experience. Cancer J Sci Am 1997 ; 1 : S9-S15
248. 248 Dillman RO, Wiemann MC, VanderMolen LA, Bury MJ, DePriest C, Church C. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic melanoma: a phase II trial of the cancer biotherapy research group (formerly the National Biotherapy Study Group). Cancer Biother Radiopharm 1997 ; 12 : 249-55
249. 249 Noble S, Goa KL. Aldesleukin (recombinant interleukin-2). A review of its pharmacological properties, clinical efficacy and tolerability in patients with metastatic melanoma. BioDrugs 1997 ; 7 : 394-422
250. 250 Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alfa and chemotherapy. Semin Oncol 1997 ; 24 : S4-39
251. 251 Kawachi S, Saida T. Complete remission of metastatic malignant melanoma by adoptive immunotherapy using immobilized anti-CD3 antibody-activated T lymphocytes and CDV chemotherapy. Biotherapy 1996 ; 10 : 561-3
252. 252 Eton O, Talpaz M, Lee KH, Rothberg JM, Brell JM, Benjamin RS. Phase II trial, of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma. Cancer 1996 ; 77 : 893-9
253. 253 Guida M, Abbate I, Musci MD, Casamassima A, Latorre A, Lorusso V et al. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: biological effects and clinical implications. Cancer Biother 1995 ; 10 : 195-203
254. 254 Buzaid AC, Legha SS, Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994 ; 21 : 23-8
255. 255 Lopez M, Carpano S, Cavaliere R, Di Lauro L, Ameglio F, Vitelli G et al. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects. Ann Oncol 1994 ; 5 : 741-6
256. 256 Dreno B, Cupissol D, Joly P, Sassolas B, Bonneterre T, Tourani JM. Ambulatory treatment of metastatic melanoma associating subcutaneous dacarbazine, interferon a and interleukin-2. J Eur Acad Dermatol Venereol 1995 ; 4 : 248-53
257. 257 Shrayer D, Koness J, Kouttab N, Bogaars H, Hearing VJ, Maizel A et al. Anti-tumor effects of polyvalent and monovalent vaccines coupled with interleukin 2 in a metastatic melanoma model. Int J Oncol 1994 ; 4 : 1121-7
258. 258 Thomas L, Bérard F, Secchi T. Diagnostic du mélanome cutané. Bull Esthet Dermatol Cosmetol 1996 ; 4 : 65-74